Paraben exposure related to Staphylococcal enterotoxin IgE sensitization, allergic rhinitis and nasal patency in children

Ha, E., Kwak, J., Kim, J. et al. Sci Rep 15, 6038 (2025). https://doi.org/10.1038/s41598-025-89095-w

Abstract

Significant association between sensitization to staphylococcal
enterotoxin and paraben exposure in children, related to
allergic rhinitis and nasal response to decongestants. 
AR Allergic rhinitis, TSST toxic shock syndrome toxin.

The study aims to investigate the link between paraben exposure, Staphylococcal enterotoxin IgE sensitization, and their combined relationship on allergic rhinitis and nasal patency in children. We assessed 276 children aged 10–12, examining their demographic backgrounds, atopy status, prevalence of allergic diseases, and serum specific IgE levels for Staphylococcal enterotoxins A, B, and toxic shock syndrome toxin (TSST). Parabens metabolites in urine samples were measured to assess exposure levels. The cohort included 276 children (mean 10.9 years), comprising 119 males and 157 females.

Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK-air Study

Sousa-Pinto B, Costa EM, Vieira RJ et al. Clin Exp Allergy. 2025 Feb 16. doi: 10.1111/cea.70004. Epub ahead of print. 

ABSTRACT

Background

Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK-air mHealth app to assess adherence to oral antihistamines (OAH), intra-nasal corticosteroids (INCS) or azelastine-fluticasone in patients with allergic rhinitis.

Methods

We included regular European MASK-air users with self-reported allergic rhinitis and reporting at least 1 day of OAH, INCS or azelastine-fluticasone. We assessed weeks during which patients answered the MASK-air questionnaire on all days. We restricted our analyses to data provided between January and June, to encompass the pollen seasons across the different assessed countries.

Evaluating the Real-World Effectiveness of Systemic Treatments in Atopic Dermatitis Using the Atopic Dermatitis Control Tool (ADCT): A Multi-Centre, Prospective Study

Lee, H. J., Woo, Y., Lee, Y. B., Lee, J. H., Kim, J. E., Lee, J. H., & Cho, S. H. (2025). Acta Dermato-Venereologica, 105, adv40704. https://doi.org/10.2340/actadv.v105.40704

Abstract

Meaningful improvement of atopic dermatitis (AD)
evaluated by Atopic Dermatitis Control Tool (ADCT).

Atopic dermatitis is a chronic skin disease affecting quality of life, sleep, and mental health. Traditional evaluation methods focus on clinical assessments, but there is a growing need for tools that incorporate patient-reported outcomes (PROs). To evaluate the effectiveness of the Atopic Dermatitis Control Tool (ADCT) in assessing disease severity in patients with moderate to severe atopic dermatitis and to compare the efficacy of systemic immunosuppressants and dupilumab in patients with moderate to severe atopic dermatitis. A prospective, observational study was conducted across seven centres in Korea, involving 112 patients with moderate to severe atopic dermatitis.

Type 2-high airway inflammation in childhood asthma distinguishes a more severe phenotype

Skov FR, Sultan T, Fischer-Rasmussen K, et al. Pediatr Allergy Immunol. 2025; 36:e70032. doi:10.1111/pai.70032

Abstract

Background

It remains unclear whether phenotyping of type 2-high (T2-high) asthma can distinguish clinical characteristics and lung function trajectories in childhood.

Objective

To explore differences between T2-high and T2-low asthma from birth to age 18 years.

Methods

We included 47 children with asthma and 165 as a control group from the Copenhagen Prospective Studies on Asthma in Childhood₂₀₀₀ mother–child cohort. T2-high and T2-low asthma was defined at age 7 by sensitization to aeroallergens, elevated eosinophilic blood count, and/or elevated fractional nitric oxide. Lung function measurements included whole-body plethysmography, spirometry, exercise test, cold air provocation, and methacholine challenge.

Biphasic anaphylaxis in a Canadian tertiary care centre: an evaluation of incidence and risk factors from electronic health records and telephone interviews

Ellis, A.K., Hossenbaccus, L., Linton, S. et al. Allergy Asthma Clin Immunol 21, 7 (2025). https://doi.org/10.1186/s13223-024-00919-2

Abstract

Background

Our previous 2007 study reported a 19.4% rate of biphasic anaphylaxis in Kingston, Ontario. Since then, few updates have been published regarding the etiology and risk factors of biphasic anaphylaxis. This study aimed to describe the incidence of and predictors of biphasic anaphylaxis in a single centre through a retrospective evaluation of patients with diagnosed anaphylaxis.

Methods

From November 2015 to August 2017, all patients who presented to the emergency department at two hospital sites in Kingston given a diagnosis of “allergic reaction,” “anaphylaxis,” “drug allergy,” or “insect sting allergy,” were evaluated. Patients were contacted sometime after ED discharge to obtain consent and confirm symptoms and timing of the reaction.

Post-Vaccination Anaphylaxis in Adults: A Systematic Review and Meta-Analysis

Pennisi F, D’Amelio AC, Cuciniello R, Borlini S, Mirzaian L, Ricciardi GE, Minerva M, Gianfredi V, Signorelli C. Vaccines. 2025; 13(1):37. https://doi.org/10.3390/vaccines13010037

Abstract

Background/Objectives: Vaccines have been recognized as one of the most effective public health interventions. However, vaccine-associated anaphylaxis, although rare, is a serious adverse reaction. The incidence of anaphylaxis related to non-COVID-19 vaccines in adults remains underreported. This systematic review and meta-analysis aim to estimate the incidence of post-vaccination anaphylaxis across various vaccines in adults. 

Methods: A comprehensive literature search of PubMed, Embase, Scopus, and Web of Science identified studies on anaphylaxis following vaccination in adults (≥18 years), excluding COVID-19 vaccines. PRISMA 2020 guidelines were followed. The protocol was registered in PROSPERO in advance (ID CRD42024566928). Random-effects and fixed-effects models were used to pool data and estimate the logit proportion, with the logit-transformed proportion serving as the effect size, thereby allowing for the calculation of event rates. 

Forest plot of the random-effects model assessing the logit proportion
among vulnerable populations (individuals with pre-existing allergies or
chronic conditions).In the forest plot, the effect sizes of
individual studies are represented in blue, while the overall
effect size is shown in green.

Results: A total of 37 studies were included in the systematic review, with 22 studies contributing to the meta-analysis, representing a combined population of 206,855,261 participants. Most studies focused on influenza vaccines (n = 15). Across all studies, 262 anaphylactic cases were reported, with 153 cases related to influenza vaccines, followed by herpes zoster virus vaccines (38 cases) and yellow fever vaccines (29 cases).

Allergen sensitization patterns: Allergic rhinitis with multimorbidity versus alone-A real-world study.

Li YT, Ye QQ, Lu YX, Yang KX, Zhang PP, Chen C, Zhou M, Feng PY, Chen ZG. Clin Transl Allergy. 2025 Jan;15(1):e70030. doi: 10.1002/clt2.70030.

Abstract

Background

Allergic rhinitis (AR) multimorbidity may need to be considered a specific disease because of distinct clinical and immunological differences from AR alone. Allergic multimorbidity often involves polysensitization, where allergen-specific immunoglobulin E (IgE) plays a significant role.

Objective

This study aims to explore differences in allergen IgE sensitization patterns between AR alone and AR multimorbidity.

Methods

A real-world case-control study was conducted with patients diagnosed with AR.

Assessment of the underreporting of rhinitis in patients with asthma: A MASK-air® real-world study

 

Sousa-Pinto B, Louis G, Vieira RJ et al. Pulmonology. 2025 Dec 31;31(1):2419216. doi: 10.1080/25310429.2024.2419216.

Abstract

Rhinitis control in the three clusters of patients with
self-reported asthma and no reported rhinitis.

Rhinitis is a common comorbidity in patients with asthma. However, the frequency of underreported rhinitis in asthma is not known. In this study, we aimed to assess the characteristics of patients with self-reported asthma and no self-reported rhinitis, as well as the extent of the underreporting of rhinitis. We performed a cross-sectional study of all MASK-airⓇ users (2015-2022, 27 countries), comparing reported symptoms and medication use in patients with (i) self-reported asthma without rhinitis ("asthma alone"), (ii) self-reported rhinitis+asthma and (iii) self-reported rhinitis without asthma ("rhinitis alone").